Literature DB >> 26730646

Molecular mechanism of inhibition of the abnormal proliferation of human umbilical vein endothelial cells by hydroxysafflor-yellow A.

Ji Wang1, Jingjing Wang1, Xixi Wang1, Li Liu1, Jinghong Hu1, Xue Yu1, Yingying Xu1, Xuyan Niu2, Zong Lin3, Yan Zhang1, Xin Zhang1, Qian Zhang1.   

Abstract

Context It has been found that hydroxysafflor-yellow A (HSYA) inhibits angiogenesis and the proliferation of abnormal human umbilical vein endothelial cells (HUVECs) in our previous study; however, the mechanism is still unclear. Objective This study investigates the mechanisms of HSYA inhibiting abnormal proliferation of HUVECs through detecting the expression of vascular endothelial growth factor (VEGF) and its receptor (KDR), and the protein expression in the Ras-Raf-MEK-ERK-signalling pathway. Materials and methods HepG2 cell cultural supernatant was used to culture HUVECs to make promote abnormal proliferation, and HSYA was added into the medium. The expression of VEGF, KDR, c-myc, N-ras and NF-κB1 in abnormal HUVEC was detected by RT-qPCR and ELISA at the mRNA and protein levels. Protein expression of ERK signal pathway was measured by Western blot. Results Compared with the abnormal proliferation of HUVECs without any treatment, HSYA inhibited the expression of VEGF and KDR in vitro. Similarly, the protein expression of Ras, p-raf, p-ERK and p-p38MARK in the abnormal HUVECs was reduced when they were treated by HSYA, especially in p-ERK, yet the total raf, ERK, p38MAPK and Akt were not changed whether HSYA existed or not. HSYA could also inhibit the expression of c-myc, N-ras, and NF-κB1. Conclusion When the abnormal HUVECs were treated with HSYA, the low expression of VEGF and KDR reduced the expression of oncogene and transcription factor through the Ras-Raf-MEK-ERK1/2 pathway of the MAPK family. This resulted in inhibiting the abnormal proliferation of HUVECs and angiogenesis.

Entities:  

Keywords:  Angiogenesis; MAPK signalling pathway; VEGF

Mesh:

Substances:

Year:  2016        PMID: 26730646     DOI: 10.3109/13880209.2015.1129541

Source DB:  PubMed          Journal:  Pharm Biol        ISSN: 1388-0209            Impact factor:   3.503


  8 in total

Review 1.  Antiangiogenic Effect of Flavonoids and Chalcones: An Update.

Authors:  Ladislav Mirossay; Lenka Varinská; Ján Mojžiš
Journal:  Int J Mol Sci       Date:  2017-12-22       Impact factor: 5.923

2.  Nucleolin mediated pro-angiogenic role of Hydroxysafflor Yellow A in ischaemic cardiac dysfunction: Post-transcriptional regulation of VEGF-A and MMP-9.

Authors:  Jiang Zou; Nian Wang; Manting Liu; Yongping Bai; Hao Wang; Ke Liu; Huali Zhang; Xianzhong Xiao; Kangkai Wang
Journal:  J Cell Mol Med       Date:  2018-03-07       Impact factor: 5.310

3.  MYC/NBS1-Mediated DNA Damage Response is Involved in the Inhibitory Effect of Hydroxysafflor Yellow A on Glioma Cells.

Authors:  Dongfang Tang; Tao Huang; Qilong Tian; Julei Wang
Journal:  Drug Des Devel Ther       Date:  2021-04-28       Impact factor: 4.162

4.  Effects and Action Mechanism of Huoxue Tongluo Formula on the Formation of Neutrophil Extracellular Traps.

Authors:  Xiaoli Zhou; Weixiang Liao; Wei Peng; Tingting Xie; Qianlu Yin; Yuhang Zheng
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-18       Impact factor: 2.650

Review 5.  Triple-negative breast cancer: new treatment strategies in the era of precision medicine.

Authors:  Song-Yang Wu; Hai Wang; Zhi-Ming Shao; Yi-Zhou Jiang
Journal:  Sci China Life Sci       Date:  2020-08-11       Impact factor: 6.038

6.  Hydroxysafflor-Yellow A Induces Human Gastric Carcinoma BGC-823 Cell Apoptosis by Activating Peroxisome Proliferator-Activated Receptor Gamma (PPARγ).

Authors:  Li Liu; Na Si; YiCong Ma; DongYu Ge; Xue Yu; AngRan Fan; Xu Wang; JingHong Hu; Peng Wei; Long Ma; ZiWei Chen; Qian Zhang; CuiLing Feng
Journal:  Med Sci Monit       Date:  2018-02-08

Review 7.  Hydroxysafflor Yellow A: A Promising Therapeutic Agent for a Broad Spectrum of Diseases.

Authors:  Hui Ao; Wuwen Feng; Cheng Peng
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-25       Impact factor: 2.629

8.  Co-delivery of deferoxamine and hydroxysafflor yellow A to accelerate diabetic wound healing via enhanced angiogenesis.

Authors:  Si-Qian Gao; Chen Chang; Jun-Jun Li; Ying Li; Xiao-Qian Niu; Dan-Ping Zhang; Long-Jian Li; Jian-Qing Gao
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.